28 Sep Likarda
Stella Vnook, Ph.D., CEO
Oct. 7 | 10:15am | FLW Ballroom G
Kansas City, MO
(Private)
Likarda is a biotech company pioneering next-generation drug and cell therapy delivery using its proprietary Core-Shell Spherification™ (CSS™) platform. This injectable hydrogel technology enables precise, localized, and extended-release delivery of cells, biologics, peptides, and small molecules—improving therapeutic durability, reducing immune responses, and enhancing patient outcomes. Likarda’s platform is uniquely designed to support subcutaneous administration, cryopreservation and dry ice shipping, and immune protection for allogeneic or off-the-shelf therapies. With applications across regenerative medicine, oncology, metabolic disease, and rare disorders, Likarda is partnering with biopharma and advanced therapy developers to solve their toughest delivery challenges and accelerate therapies to market.
